1,128 assets in Non-Small Cell Lung Carcinoma

Therapeutic assets addressing Non-Small Cell Lung Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan Non-Small Cell Lung Carcinoma	Hunan Province Tumor Hospital	P3	B (63)
Sugemalimab Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P3	B (63)
Sunvozertinib Non-Small Cell Lung Carcinoma	Dizal (Jiangsu) Pharmaceutical Co., Ltd.	P3	B (63)
Tepotinib Non-Small Cell Lung Carcinoma	Memorial Sloan Kettering Cancer Center	P3	B (63)
Toripalimab Non-Small Cell Lung Carcinoma	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School	P3	B (63)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Non-Small Cell Lung Carcinoma	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	P3	B (62)
Aspirin Non-Small Cell Lung Carcinoma	Shanghai Chest Hospital	P3	B (62)
Avutometinib Non-Small Cell Lung Carcinoma	Verastem, Inc.	P2	B (62)
Cabozantinib Non-Small Cell Lung Carcinoma	Jun Zhang, MD, PhD	P3	B (62)
Cobolimab Non-Small Cell Lung Carcinoma	GlaxoSmithKline	P2/3	B (62)
Defactinib Non-Small Cell Lung Carcinoma	Verastem, Inc.	P2	B (62)
Famitinib Non-Small Cell Lung Carcinoma	Second Affiliated Hospital of Nanchang University	P3	B (62)
gfh375 Non-Small Cell Lung Carcinoma	Genfleet Therapeutics (Shanghai) Inc.	P3	B (62)
hs-10241 Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P3	B (62)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P3	B (62)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Non-Small Cell Lung Carcinoma	University of Chicago	P3	B (62)
Ivonescimab Non-Small Cell Lung Carcinoma	European Organisation for Research and Treatment of Cancer - EORTC	P3	B (62)
Jmkx001899 Non-Small Cell Lung Carcinoma	Jemincare	P3	B (62)
Muamycin Non-Small Cell Lung Carcinoma	City of Hope Medical Center	P3	B (62)
Nepenthe Non-Small Cell Lung Carcinoma	Hacettepe University	P4	B (62)
ose2101 Non-Small Cell Lung Carcinoma	OSE Immunotherapeutics	P3	B (62)
Oxaliplatin Non-Small Cell Lung Carcinoma	Qilu Pharmaceutical Co., Ltd.	P3	B (62)
Panitumumab Non-Small Cell Lung Carcinoma	Astellas Pharma Inc	P2	B (62)
Pyrotinib Non-Small Cell Lung Carcinoma	RemeGen Co., Ltd.	P3	B (62)
Retifanlimab Non-Small Cell Lung Carcinoma	University of California, San Diego	P3	B (62)
Ssgj-707 Non-Small Cell Lung Carcinoma	Shenyang Sunshine Pharmaceutical Co., LTD.	P3	B (62)
Trastuzumab Non-Small Cell Lung Carcinoma	Fate Therapeutics	P3	B (62)
Utidelone Non-Small Cell Lung Carcinoma	Beijing Biostar Pharmaceuticals Co., Ltd.	P3	B (62)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Non-Small Cell Lung Carcinoma	University of Chicago	P3	B (61)
Irinotecan Non-Small Cell Lung Carcinoma	Jiangsu Hansoh Pharmaceutical Co., Ltd.	P2	B (61)
Metformin Non-Small Cell Lung Carcinoma	Instituto Nacional de Cancerologia de Mexico	P3	B (61)
Pegfilgrastim Non-Small Cell Lung Carcinoma	University of California, Irvine	P4	B (61)
Selumetinib Non-Small Cell Lung Carcinoma	AstraZeneca	P3	B (61)
Sorafenib Non-Small Cell Lung Carcinoma	Jian Chen	P3	B (61)
Thalidomide Non-Small Cell Lung Carcinoma	Henan Cancer Hospital	P4	B (61)
Tiragolumab Non-Small Cell Lung Carcinoma	Hoffmann-La Roche	P3	B (61)
Tisotumab Vedotin Non-Small Cell Lung Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P2	B (61)
Trastuzumab Deruxtecan Non-Small Cell Lung Carcinoma	National Cancer Institute (NCI)	P3	B (61)
Trastuzumab Emtansine Non-Small Cell Lung Carcinoma	Guangzhou Institute of Respiratory Disease	P2	B (61)
Tucidinostat Non-Small Cell Lung Carcinoma	Guangdong Association of Clinical Trials	P2	B (61)
Abemaciclib Non-Small Cell Lung Carcinoma	Tango Therapeutics, Inc.	P3	B (60)
Abp 234 Non-Small Cell Lung Carcinoma	Amgen	P3	B (60)
ak112 Non-Small Cell Lung Carcinoma	Akeso	P3	B (60)
al8326 Non-Small Cell Lung Carcinoma	Advenchen Pharmaceuticals, LLC.	P2	B (60)
Askc202 Non-Small Cell Lung Carcinoma	Jiangsu Aosaikang Pharmaceutical Co., Ltd.	P3	B (60)
Axitinib Non-Small Cell Lung Carcinoma	Shanghai Pulmonary Hospital, Shanghai, China	P3	B (60)
Brigatinib Non-Small Cell Lung Carcinoma	M.D. Anderson Cancer Center	P3	B (60)
Ceritinib Non-Small Cell Lung Carcinoma	Pfizer	P3	B (60)
Cyclophosphamide Non-Small Cell Lung Carcinoma	University of Pennsylvania	P3	B (60)
Drug: Furmonertinib Non-Small Cell Lung Carcinoma	Allist Pharmaceuticals, Inc.	P3	B (60)

Showing 101 to 150 of 1,128 assets

PreviousPage 3 of 23Next